BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 6583305)

  • 1. Pharmacological basis of akinesia in Parkinson's disease.
    Narabayashi H
    J Neural Transm Suppl; 1983; 19():143-51. PubMed ID: 6583305
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Festination and freezing].
    Imai H
    Rinsho Shinkeigaku; 1993 Dec; 33(12):1307-9. PubMed ID: 8174332
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Symptoms and side effects in the course of Parkinson's disease.
    Birkmayer W; Danielczyk W; Riederer P
    J Neural Transm Suppl; 1983; 19():185-99. PubMed ID: 6583306
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Neurochemical basis for pathological motor activity].
    Hole K
    Tidsskr Nor Laegeforen; 1974 Jan; 94(1):11-7. PubMed ID: 4362478
    [No Abstract]   [Full Text] [Related]  

  • 5. Peculiarities of L: -DOPA treatment of Parkinson's disease.
    Kostrzewa RM; Nowak P; Kostrzewa JP; Kostrzewa RA; Brus R
    Amino Acids; 2005 Mar; 28(2):157-64. PubMed ID: 15750845
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reevaluation of levodopa therapy for the treatment of advanced Parkinson's disease.
    Yokochi M
    Parkinsonism Relat Disord; 2009 Jan; 15 Suppl 1():S25-30. PubMed ID: 19131038
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Biochemical aspects of involuntary movements (author's transl)].
    Nakamura S; Kameyama M
    No To Shinkei; 1981 Dec; 33(12):1177-85. PubMed ID: 7034752
    [No Abstract]   [Full Text] [Related]  

  • 8. Parkinson's disease. Diagnosis and the initiation of therapy.
    Bhat V; Weiner WJ
    Minerva Med; 2005 Jun; 96(3):145-54. PubMed ID: 16175158
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Motor fluctuations in Parkinson's disease.
    Weiner WJ
    Rev Neurol Dis; 2006; 3(3):101-8. PubMed ID: 17047575
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Recent progress in development of psychotropic drugs (3)--Antiparkinsonian agents applied in the treatment of Parkinson's disease or are under investigation for patients or model animals].
    Nomoto M
    Nihon Shinkei Seishin Yakurigaku Zasshi; 1996 Aug; 16(4):113-22. PubMed ID: 8905800
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Motor symptoms in Parkinson disease].
    Larsen JP; Beiske AG; Bekkelund SI; Dietrichs E; Tysnes OB; Vilming ST; Aasly JO
    Tidsskr Nor Laegeforen; 2008 Sep; 128(18):2068-71. PubMed ID: 18846123
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Swim-test as a function of motor impairment in MPTP model of Parkinson's disease: a comparative study in two mouse strains.
    Haobam R; Sindhu KM; Chandra G; Mohanakumar KP
    Behav Brain Res; 2005 Sep; 163(2):159-67. PubMed ID: 15941598
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Three types of akinesia in the progressive course of Parkinson's disease.
    Narabayashi H
    Adv Neurol; 1993; 60():18-24. PubMed ID: 8093577
    [No Abstract]   [Full Text] [Related]  

  • 14. Clinical neurophysiology of akinesia.
    Hallett M
    Rev Neurol (Paris); 1990; 146(10):585-90. PubMed ID: 2263821
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Mesolimbic and mesocortical pathways in Parkinson disease].
    Yokochi M
    Brain Nerve; 2007 Sep; 59(9):943-51. PubMed ID: 17886476
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pulsatile stimulation of dopamine receptors and levodopa-induced motor complications in Parkinson's disease: implications for the early use of COMT inhibitors.
    Olanow CW; Obeso JA
    Neurology; 2000; 55(11 Suppl 4):S72-7; discussion S78-81. PubMed ID: 11147513
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Monoamines in the human neostriatum: topographic distribution in normals and in Parkinson's disease and their role in akinesia, rigidity, chorea, and tremor.
    Fahn S; Libsch LR; Cutler RW
    J Neurol Sci; 1971 Dec; 14(4):427-55. PubMed ID: 5125758
    [No Abstract]   [Full Text] [Related]  

  • 18. [Parkinson's disease and parkinsonian syndromes].
    Pollack P; Gaio JM; Perret J
    Rev Prat; 1989 Mar; 39(8):647-51. PubMed ID: 2727571
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The 'magic' of L-dopa: why is it the gold standard Parkinson's disease therapy?
    Mercuri NB; Bernardi G
    Trends Pharmacol Sci; 2005 Jul; 26(7):341-4. PubMed ID: 15936832
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Biochemical and clinical correlations in Parkinson's disease].
    Barbeau A
    Rev Neurol (Paris); 1972 Aug; 127(2):253-64. PubMed ID: 4603361
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.